Essity (ESSITYB SS): Synthetic Expert Call Transcript (21 Sep 2026)
The strategic review of the Consumer Tissue business (representing SEK 43,537m or 31% of 2025 net sales) is highly likely to culminate in a...
101 Views
Essity: Separating the Tissue from the Value
Essity's Tissue review is gathering pace. We look at what a separation could mean for RemainCo and whether the current price leaves enough on the...
89 Views
Primer: Essity (ESSITYB SS) - Aug 2026
Essity is strategically repositioning its portfolio towards higher-margin Health & Medical and Personal Care segments, evidenced by the...
99 Views
Industrivärden's Q1 2025: NAV Evolution, Discount, Target NAV, Replication
​Industrivärden offers long-term exposure to Swedish industrial blue chips with potential for upside as market sentiment stabilizes and core assets...
551 Views
Vinda International (3331 HK): Essity’s Stake Attracts More Potential Bidders
Vinda’s improving performance has supported the increasing list of potential bidders. The most likely bid structure is the acquisition of Essity’s...
778 Views